OsteoSight Hip (v1) is an AI-enabled medical device from Naitive Technologies Ltd that the U.S. FDA cleared through 510(k) K251408 on September 2, 2025. Its lead review panel is Radiology and its primary product code is SAO (Radiology Software For Opportunistic Evaluation Of Low Bone Mineral Density).
See also FDA-cleared AI radiology devices in 2025, all FDA AI clearances in 2025, top radiology AI devices.
Key facts
| Submission number | K251408 |
|---|---|
| Pathway | 510(k) |
| Date of final decision | |
| Company (FDA list) | Naitive Technologies Ltd |
| Lead review panel | Radiology |
| Primary product code | SAO — Radiology Software For Opportunistic Evaluation Of Low Bone Mineral Density |
| Applicant (openFDA) | Naitive Technologies, Ltd. |
| Applicant location | Cambridge, GB |
| Device class | Class 2 |
| Regulation number | 21 CFR 892.1171 |
| Decision code | SESE |
| Submission type | Traditional |
Source: FDA AI-Enabled Medical Devices list and openFDA.
What this means
A 510(k) is a premarket submission showing the device is substantially equivalent to a legally marketed predicate device. A cleared 510(k) means FDA agreed with that equivalence. OsteoSight Hip (v1) went through this pathway (K251408).
openFDA lists it as a Class 2 device under 21 CFR 892.1171. Class II devices are moderate risk and are subject to general and special controls.
Product code SAO covers 3 devices on the FDA AI list. By decision date, this device is #2 of 3 under that code. Naitive Technologies Ltd has 1 AI-enabled device on the list, and the Radiology panel accounts for 1,230 in total.
Being on this list doesn't describe how well the device works clinically. Check the FDA record for its indications for use.